【慢速】每日听读 ｜世卫组织：减肥药或将列入基本药物清单 全球超6.5亿成年人肥

　　    

　　为什么很多人听力无法提高？

　　原因可能有：

　　?没有选对材料，听过难或简单的听力材料；

　　?没有刻意训练，只是不断听，没有纠正自己的错误；

　　?大多数人都会涉及到的一个问题，坚持不下来。

　　关注普特的小伙伴们都知道普特君一直开设听力训练营来和大家一起坚持练习听力，目前为止已经开设了十七期听力训练营，这次普特英语对听力训练营做了内容上的重大调整升级，全新的第三季第四期听力训练营（21天听力进阶训练）正式开始啦！只需49元！

　　21天听力持续进阶训练：

　　1.每课共6个20~30秒的BBC原声音频，慢速-中速-常速进阶训练，逐步攻克听力难关

　　2.老师视频讲解、分析重点，配有学习笔记+译文参考，新增课外拓展阅读

　　3.BBC双语纪录片字幕填空训练，每课一句重点跟读练习，巩固学习成果

　　??识别二维码参与课程??

　　

　　Drugs that fight obesity could for the first time be included on the World Health Organization's (WHO) "essential medicines list."The United Nations health agency told Reuters the list is used to guide government purchasing decisions in low- and middle-income countries.A group of WHO advisers will examine new requests for drugs to be included next month. The latest list of essential medicines is set to be released in September.The request to consider obesity drugs came from three doctors and a researcher in the United States. Their request covers the active ingredient liraglutide, which is used in the obesity drug Saxenda. The drug, made by Novo Nordisk, is set to come off patent soon. The consideration is meant to permit the availability of less costly versions of such drugs.WHO advisers could reject the request or wait for more evidence.But if they approve the request to include Saxenda and any future drug versions, it would mark a new method of dealing with worldwide obesity.However, some public health experts warn against introducing such medicines to the public as a solution to a complex condition that is still not completely understood.The WHO said the group of experts would consider the evidence for liraglutide over the coming months. The group may also look into other kinds of weight-loss treatments in the future.The WHO found over 650 million adults worldwide are obese, more than three times the rate in 1975. Another 1.3 billion people worldwide are overweight. Seventy percent of obese and overweight people live in low- and middle-income countries.Expanding its reachIncluding obesity drugs among the WHO's essential medicines could make a major difference in poorer populations. Experts say that adding drugs for the disease HIV to the list in 2002 helped make such drugs more widely available to patients in lower-income countries.The doctors and the researcher who requested the consideration wrote, "At present, there are no medications included in the (list) that specifically target weight loss for the ongoing global burden of obesity."They argue that the lack of weight-loss treatments goes against the idea of worldwide health equality. Poorer nations, they added, are seeing increased deaths from weight-related illnesses.About the drugsSaxenda is a once-daily injection. It has been shown to help people reduce 5 to 10 percent of their body weight. It is $450 per month in the United States and $150 per month in Europe.Another drug made by Novo Nordisk, Wegovy, is a weekly injection. It costs more than $1,300 a month in the United States. People using it have lost up to 15 percent of their weight.At the moment, Wegovy is in short supply. Novo is mainly working toward Wegovy's launch in the United States and other wealthy markets.Both drugs belong to a class of medicines called GLP-1 receptor agonists. Such drugs have been used for years to treat diabetes. The drug affects hunger signals to the brain and slow the rate at which a person's stomach empties. As a result, people feel fuller longer.For both Saxenda and Wegovy, there is a lack of long-term safety and effectiveness data for obesity. Studies suggest people will likely have to take the drugs for the rest of their lives to keep the weight off.Novo Nordisk said in a statement it was not involved in the request to consider liraglutide for the WHO list. It added, "We welcome the WHO review and look forward to the readout and decision."I'm Gregory Stachel.

　　

　　

　　21天打卡等你来挑战~